Clinical trials · California
Cardiomyopathies clinical trials in California
We’re tracking 36 recruiting cardiomyopathies studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
La Jolla, CaliforniaAges 18–85 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
La Jolla, CaliforniaAges 18 years+ - NCT07606274RecruitingPhase 1/Phase 2
Study of NVC-001 for heart muscle disease caused by LMNA gene change
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Los Angeles, CaliforniaAges 18 years+ - NCT04476901RecruitingPhase 2
Study of donor stem cell treatment for non-ischemic heart failure
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
Stanford, CaliforniaAges 18–80 - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06412666RecruitingPhase 2/Phase 3
Aficamten for teens with obstructive hypertrophic cardiomyopathy
This trial tests a new medicine called aficamten for teenagers with a heart condition that makes the heart muscle too thick and blocks blood flow. The medicine may help make the heart pump more easily and improve symptoms like shortness of breath or chest pain.
Los Angeles, CaliforniaAges 12–17 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT05112237Recruiting
Study of children’s heart disease caused by MYBPC3 gene changes
This is an observational study that follows children under 18 with cardiomyopathy caused by certain MYBPC3 gene mutations. It aims to better understand how the disease changes over time, which may help future treatments be better targeted.
San Diego, CaliforniaAges birth–18 years - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT05818605Recruiting
Exercise training for people with hypertrophic heart muscle
This study tests whether a 24-week exercise program can improve exercise tolerance in people with hypertrophic cardiomyopathy (a thickened heart muscle). You may be asked to use phone-based tools and complete surveys during training.
San Francisco, CaliforniaAges 18–80 - NCT05885412RecruitingPhase 1
Study drug for heart rhythm problems in PKP2 heart disease
This Phase 1 trial tests RP-A601 (a gene-delivery type treatment) to see if it can reduce dangerous heart rhythm problems in people with PKP2-related arrhythmogenic cardiomyopathy (ACM). Because it’s an early safety/dose study, the main goal is to check safety and how the body responds.
La Jolla, CaliforniaAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
San Diego, CaliforniaAges 18–90 - NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
San Francisco, CaliforniaAges 14–65 - NCT06935253Recruiting
AI to Improve Cardiology Care
This trial tests whether large language models (a type of AI that understands human language) can help cardiologists give better care. If you are a qualified cardiologist who currently treats patients, you may be eligible.
Palo Alto, CaliforniaAges 18 years+ - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
San Francisco, CaliforniaAges 18 years+ - NCT07137338RecruitingPhase 1
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
San Diego, CaliforniaAges 18–65 - NCT07674758Recruiting
Understanding heart risk in Duchenne and Becker muscular dystrophy
This study looks at heart health in people with Duchenne or Becker muscular dystrophy to find better ways to predict and track heart problems. The goal is to improve future treatment trials.
Sacramento, CaliforniaAges Any age - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Beverly Hills, CaliforniaAges 18 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
La Jolla, CaliforniaAges 18 years+ - NCT06080074RecruitingPhase 2
Emergency heart-lung machine study for children with severe heart failure
This study tests a specific heart-lung machine called Cardiohelp to help children with severe heart failure. It looks at how well the machine works and whether a blood thinner (either heparin or bivalirudin) is safer and more effective.
Palo Alto, CaliforniaAges birth–16 years - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
La Jolla, CaliforniaAges 18 years+ - NCT03910569Recruiting
Takotsubo heart event registry and blood protein study
This study enrolls people who have been diagnosed with Takotsubo (a temporary, stress-related heart condition). It aims to better understand Takotsubo by collecting your medical records and analyzing proteins, which may help improve care in the future.
Los Angeles, CaliforniaAges 18 years+ - NCT05034432RecruitingPhase 4
Test treatment for dangerous heart rhythm episodes in LVAD patients
This trial studies a procedure to fix abnormal heart rhythms (ventricular tachycardia or ventricular fibrillation) in people who have an LVAD and a defibrillator (ICD) or an alternative device. It may help prevent future dangerous rhythm episodes after LVAD treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05427370Recruiting
Compare bypass or stent treatment in weak heart patients
This study compares two ways to restore blood flow to the heart—bypass surgery (CABG) or stent procedure (PCI)—in people with a weak pumping heart. It looks at which approach works best when the heart muscle is not pumping well and there are multiple blocked heart arteries.
Los Angeles, CaliforniaAges 18 years+
Cardiomyopathies trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- Cedars-Sinai Medical Center · 8 studies
- University of California, San Francisco · 7 studies
- Stanford University · 5 studies
- University of California San Diego Health · 4 studies
- University of California, Los Angeles (UCLA) · 3 studies
- Children's Hospital Los Angeles · 2 studies
- Clinical Trial Site · 2 studies
- UC San Diego Medical Center · 2 studies
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in California?
- Yes. We're currently tracking 36 recruiting cardiomyopathies studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.